Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Acronyms BRAVE I
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 07 Aug 2018 Status changed from planning to not yet recruiting.
    • 23 Jul 2018 According to Eli lilly Media release, Lilly plans to initiate this trial in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top